BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Core Insights - BioNTech SE and Bristol Myers Squibb Co shared interim Phase 2 data on pumitamig plus chemotherapy for untreated extensive-stage small cell lung cancer, showing a 76.3% confirmed overall response rate and a 100% disease control rate [1][2] Group 1: Clinical Data - Among 38 evaluable patients, the regimen achieved a 76.3% confirmed overall response rate, with 85% at 20 mg/kg and 66.7% at 30 mg/kg [1] - The average tumor shrinkage was reported at 56.7%, with nearly 90% of patients showing early tumor shrinkage [1] - Median progression-free survival was recorded at 6.8 months, while overall survival data is not yet mature [2] Group 2: Safety Profile - The safety profile of pumitamig was manageable, with no new safety signals identified [3] - Grade ≥3 pumitamig-related adverse events occurred in one patient at the lower dose and five at the higher dose [3] Group 3: Ongoing Trials - A Phase 3 trial, ROSETTA-LUNG-01, is currently underway, comparing pumitamig plus chemotherapy against atezolizumab plus chemotherapy in first-line extensive-stage small cell lung cancer [3] Group 4: Market Reaction - Following the announcement, BNTX stock decreased by 8.16% to $103.28, while BMY stock fell by 1.67% to $46.36 [3]